Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Conditions
Interventions
Fostamatinib 150 mg
Fostamatinib 100 mg
+1 more
Locations
20
United States
Stanford University Medical
Palo Alto, California, United States
Nephrology Associates PC, University Hospital, Professional Center 1
Augusta, Georgia, United States
Ohio State University
Columbus, Ohio, United States
Southeast Renal Research Institute
Chattanooga, Tennessee, United States
Medical University of Graz
Graz, Styria, Austria
Medical University Vienna, Nephrology
Vienna, Austria
Start Date
October 1, 2014
Primary Completion Date
March 23, 2018
Completion Date
November 12, 2018
Last Updated
June 27, 2019
NCT05797610
NCT05234463
NCT06740526
NCT06767592
NCT06065852
NCT03001947
Lead Sponsor
Rigel Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions